Pembrolizumab plus chemotherapy for cervical cancer
In this exploratory analysis of the KEYNOTE-826 randomized clinical trial, the 5-year data confirm the durability of benefit and reinforce pembrolizumab plus chemotherapy (with or without bevacizumab) as a first‑line standard‑of‑care option for recurrent and metastatic cervical cancer.
Evidence level: Állatkísérletes. Állatmodellben vizsgálták.
Related signals
- A multinational cross-sectional study on human papillomavirus and cervical cancer knowledge, vaccination attitudes, and risk factors in the Middle East
- Genomic features of cervical cancer
- Screening for Cervical Cancer
- Cervical cancer: Epidemiology, risk factors and screening
- Cervical Cancer Screening in Transition: Global Challenges and Local Realities